TORL-5-700
/ TORL Biotherap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 12, 2026
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
(clinicaltrials.gov)
- P1/2 | N=155 | Recruiting | Sponsor: TORL Biotherapeutics, LLC | Not yet recruiting ➔ Recruiting
Enrollment open • First-in-human • Monotherapy • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
February 28, 2026
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
(clinicaltrials.gov)
- P1/2 | N=155 | Not yet recruiting | Sponsor: TORL Biotherapeutics, LLC
First-in-human • Monotherapy • New P1/2 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 2
Of
2
Go to page
1